UNSPSC 51161540: Flufylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C21H24FN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O8G173034U, chemically known as 1h-purine-2,6-dione, 7-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-3,7-dihydro-1,3-dimethyl- but generally known as flufylline, which bears US NIH Compound Identifier 71255. European Medicines Agency schedules Flufylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07689MIG.

UNSPSC 51161540 Flufylline is a Commodity code covering pharmaceutical products supplied through state and local cooperative purchasing frameworks. State and local governments buy this product as part of multistate pharmaceuticals procurement agreements that aggregate demand across participating jurisdictions to negotiate volume pricing and ensure consistent supply to healthcare facilities, clinics, correctional institutions, and other public-sector entities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active under this code, managing contracts that serve not only Minnesota but also participating states including Oregon. Work under the code involves manufacturers submitting comprehensive product specifications including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations; manufacturers must maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), hold contractual relationships with authorized wholesalers, and offer flexible pricing options such as flat price, net price formats, or WAC-minus pricing structures.

The code shows recent activity concentrated in the Upper Midwest and Pacific Northwest through MMCAP's multistate reach. The Minnesota Department of Administration issued an RFP (Solicitation S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities. Awarded vendors must be available in the marketplace by May 15, 2026, with resulting contracts effective July 1, 2026. Evaluation criteria emphasize price competitiveness (75 percent weight), fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, and products must comply with FDA requirements with expiration dates at least one year from manufacture and minimum six-month shelf life. The contract term is two years for new vendors with optional MMCAP extensions, or aligned to existing expiration dates through June 30, 2028 for incumbent responders.